Treatment of Darier disease with oral alitretinoin.

Abstract

Darier disease (DD) is an autosomal dominant skin disease. Treatment is often difficult and unsatisfactory because of the chronic nature of the condition and the irritant potential of various therapeutic agents. Systemic vitamin A derivatives such as acitretin and isotretinoin are the treatment of choice, but their use is often limited by class-specific side-effects. Alitretinoin (9-cis-retinoic acid), has antiproliferative and anti-inflammatory potential, and is licensed for the systemic treatment of chronic hand eczema in a number of countries. Unlike acitretin, alitrenoin requires contraception in women of childbearing age to be extended for only 1 month after the end of treatment. There is evidence that alitretinoin might be a well-tolerated alternative for the systemic treatment of various retinoid-responsive skin diseases. We present two cases of women with refractory DD successfully treated with alitretinoin without marked side-effects, who both obtained near-complete remission of their skin lesions.

• Authors: V Letulé, T Herzinger, T Ruzicka, S Molin
• Journal: Clinical and experimental dermatology (Clin Exp Dermatol) Vol. 38 Issue 5 Pg. 523-5 (Jul 2013) ISSN: 1365-2230 [Electronic] England
• PMID: 23777494 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2013 British Association of Dermatologists.

Chemical References

• Dermatologic Agents
• Alitretinoin
• Tretinoin

Topics

• Administration, Oral
• Adult
• Alitretinoin
• Darier Disease (drug therapy)
• Dermatologic Agents (administration & dosage)
• Female
• Humans
• Treatment Outcome
• Tretinoin (administration & dosage)